Along-term Study of OPC-262 in Patients With Type 2 Diabetes
Along-term Study of OPC-262 in Patients With Type 2 Diabetes
The purpose of this clinical study is to evaluate the safety of OPC-262 (2.5 mg and 5 mg) in
 patients with type 2 diabetes by long-term administration orally for 52 weeks and to evaluate
 the efficacy of OPC-262
Inclusion Criteria:

 -  Patients who completed Study 262-09-001 (namely, patients who visited the hospital at
 visit Week 24）

 -  Patients who are capable of giving informed consent prior to participating in this
 clinical study

 -  Patients who are able to take contraceptive measures to avoid pregnancy of the patient
 or the patient's partner for the entire study period and for 4 weeks after the study
 (end of the post-observation period)

 Exclusion Criteria:

 -  Patients who withdrew from Study 262-09-001

 -  Patients who experienced serious adverse events that the relationship with the study
 drug was not denied in Study 262-09-001

 -  Patients who experienced serious adverse events that the relationship with the study
 drug are denied in Study 262-09-001 and whose symptoms are still emerged at the time
 of initiation of this study

 -  Patients who met the exclusion criteria of Study 262-09-001 during the study period of
 Study 262-09-001

 -  Female patients who wish to become pregnant during the study period of Study
 262-09-002 or within 4 weeks after the study

 -  Patients otherwise judged by the investigator or subinvestigator to be inappropriate
 for inclusion in the study